Solid tumors
Conditions
Interventions
None listed
Sponsors
Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) The published study designed as a randomized clinical trial (RCT). (2) The experimental group of the study was treated with at least one type of ICIs with or without other systemic chemotherapy and the control group. (3) The study with three arms where ICI is included at least one arm. (4) The patients were clinically diagnosed with any solid tumor. (5) The study illustrates the outcome of myositis. (6) Only full-text papers are used to analyze.
Exclusion criteria
Exclusion criteria: (1) Systematic review or meta-analysis articles. (2) Retrospective analysis. (3) Single prospective cohort study without a control group. (4) Non-RCT. (5) The republished research literature is excluded unless the research includes new findings related to adverse events listed in inclusion criteria. (6) Studies with no or insufficient safety results at the time of the literature search. (7) Studies published in languages other than English.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The odds ratio (OR) of any grade myositis will be calculated. Meta-analysis will be performed to compare the incidence of myositis between the treatment arm with ICIs and the arm with chemotherapy. | — |
Countries
Japan
Contacts
Public ContactKaoru Minegishi
Yokohama City University Graduate School of Medicine Department of Stem Cell and Immune Regulation
Outcome results
None listed